Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8(1):2185. doi:10.1038/s41467-017-02329-y
Liu D, Abbosh P, Keliher D, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017;8(1):2193. doi:10.1038/s41467-017-02320-7
Lokki I, Daly E, Triebwasser M, et al. Protective Low-Frequency Variants for Preeclampsia in the Fms Related Tyrosine Kinase 1 Gene in the Finnish Population. Hypertension. 2017;70(2):365-371. doi:10.1161/HYPERTENSIONAHA.117.09406
Huang H, Fang M, Jostins L, et al. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 2017;547(7662):173-178. doi:10.1038/nature22969
Hall AB, Yassour M, Sauk J, et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 2017;9(1):103. doi:10.1186/s13073-017-0490-5
Robinson MR, English G, Moser G, et al. Genotype-covariate interaction effects and the heritability of adult body mass index. Nat Genet. 2017;49(8):1174-1181. doi:10.1038/ng.3912
Wang SH, Hsiao PC, Yeh LL, et al. Polygenic risk for schizophrenia and neurocognitive performance in patients with schizophrenia. Genes Brain Behav. 2018;17(1):49-55. doi:10.1111/gbb.12401
Izar B, Sharfman W, Hodi S, et al. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med. 2017;6(8):1904-1914. doi:10.1002/cam4.1140
Ratanatharathorn A, Boks MP, Maihofer AX, et al. Epigenome-wide association of PTSD from heterogeneous cohorts with a common multi-site analysis pipeline. Am J Med Genet B Neuropsychiatr Genet. 2017;174(6):619-630. doi:10.1002/ajmg.b.32568
Huang AY, Yu D, Davis LK, et al. Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. Neuron. 2017;94(6):1101-1111.e7. doi:10.1016/j.neuron.2017.06.010